Literature DB >> 2431752

Cortical metabolism, acetylcholinesterase staining and pathological changes in Alzheimer's disease.

E G McGeer, P L McGeer, H Kamo, H Tago, R Harrop.   

Abstract

The local cerebral metabolic rate for glucose (LCMRgl) was determined by positron emission tomography (PET) using the 18F-fluorodeoxyglucose method in a series of Alzheimer patients and normal controls. The LCMRgl declined in the cerebral cortex with age, but the decrement was significantly greater in the clinically diagnosed Alzheimer's cases. Comparison of PET and psychological data indicated that, as the disease progressed clinically, the reduction in cortical LCMRgl and the number of cortical regions involved also increased. Variable regions of cortex were involved in the early stages but the temporal, parietal and frontal regions were most typically affected. One case coming to autopsy showed that the severity of the LCMRgl decline paralleled loss of neurons in the cortex and their replacement with astroglia. A case of Pick's disease coming to autopsy had shown a different and highly characteristic pattern of cortical metabolic defect. In this case also a poor metabolic rate was associated with extensive gliosis. Acetylcholinesterase (AChE) staining of the cerebral cortex in elderly normals and Alzheimer's disease cases with a new, highly sensitive method showed that in Alzheimer's disease there was an extensive loss of AChE-positive fibers with senile plaques frequently incorporating AChE-positive fiber debris. AChE staining of the substantia innominata area, where the cells giving rise to these neocortical fibers are presumably located, also showed evidence of degenerating cells and fibers.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431752     DOI: 10.1017/s0317167100037227

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  7 in total

1.  Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Hiroyasu Akatsu; Eric E Abrahamson; Zhiping Mi; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2015-08-21       Impact factor: 1.906

2.  Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy.

Authors:  S J Kish; L Schut; J Simmons; J Gilbert; L J Chang; M Rebbetoy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-04       Impact factor: 10.154

Review 3.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

4.  Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains.

Authors:  M A Morán; E J Mufson; P Gómez-Ramos
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 5.  Mechanism of Alzheimer's disease: arguments for a neurotransmitter-aluminium complex implication.

Authors:  R Deloncle; O Guillard
Journal:  Neurochem Res       Date:  1990-12       Impact factor: 3.996

Review 6.  The role of clinical neuropsychology in the neurological diagnosis of Alzheimer's disease.

Authors:  H Spinnler; S Della Sala
Journal:  J Neurol       Date:  1988-05       Impact factor: 4.849

Review 7.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.

Authors:  Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam
Journal:  J Neurochem       Date:  2021-08-06       Impact factor: 5.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.